ReviewMolecular cancer2026
Cuproptosis in inflammation and cancer: molecular mechanisms and therapeutic targets.
Review in Molecular cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Cellular processes depend on Copper(Cu) homeostasis, but overload of Cu in cells leads to the disruption of that balance and induces a specialized model of regulated cell death known as cuproptosis. As opposed to the conventional cell death modalities, this mechanism features the connection of Cu ions with fatty-acylated elements of the TCA cycle, which subsequently promotes proteotoxic clustering and dysfunction of the mitochondria. Cuproptosis has a distinct and regulated pathway that is not responsive to standard cell demise inhibitors, which warrant its potential role in a number of pathophysiological mechanisms, specifically in the pathogenesis of inflammatory conditions and cancer. However, the disease-specific regulatory networks of its functioning cannot be comprehensively studied, and it has been a great challenge in regard to designing specific therapeutic developments. This paper critically analyzes the regulatory processes of copper equilibrium and cuproptosis, focusing on the important regulatory genes and their interaction networks. We describe pathological implications of cuproptosis in inflammation and malignancies, outline the recent intervention methods, and address the limitations of the current research such as lack of in vivo models and biomarkers. Not only do we offer a systematic source of information about biological importance of cuproptosis but also suggest novel knowledge about the specific treatment of inflammation and cancer which has a great theoretical value and promising opportunities of its practical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.